.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
AstraZeneca
Teva
US Department of Justice
Deloitte
Covington
QuintilesIMS
Fish and Richardson
Cantor Fitzgerald
Julphar

Generated: December 12, 2017

DrugPatentWatch Database Preview

LATISSE Drug Profile

« Back to Dashboard

Which patents cover Latisse, and what generic alternatives are available?

Latisse is a drug marketed by Allergan and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in ten countries and three supplementary protection certificates in three countries.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

Summary for LATISSE

Drug patent expirations by year for LATISSE

Pharmacology for LATISSE

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog

Medical Subject Heading (MeSH) Categories for LATISSE

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LATISSE

Drugname Dosage Strength RLD Submissiondate
bimatoprosTopical Solution0.03%Latisse5/3/2010

Non-Orange Book Patents for Tradename: LATISSE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,351,404Method of enhancing hair growth► Subscribe
7,388,029Compositions and methods for treating hair loss using non-naturally occurring prostaglandins► Subscribe
8,926,953Method of enhancing hair growth► Subscribe
8,298,518Method of enhancing hair growth► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LATISSE

Country Document Number Estimated Expiration
Australia2012261499► Subscribe
Japan2014043451► Subscribe
World Intellectual Property Organization (WIPO)0174315► Subscribe
Canada2475106► Subscribe
Australia2008203212► Subscribe
European Patent Office1267807► Subscribe
European Patent Office2250996► Subscribe
China100384425► Subscribe
Germany60115000► Subscribe
Japan2005521672► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LATISSE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00099Netherlands► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C0033France► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
C/GB02/035United Kingdom► SubscribePRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Baxter
UBS
Dow
Moodys
Medtronic
Boehringer Ingelheim
Argus Health
Healthtrust
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot